AbbVie, Enanta Pharma rise after US FDA approves pediatric use of hepatitis C drug
View all comments(0)
Shares of drugmaker AbbVie ABBV.N up 1.5% at $192.40 and biotech company Enanta Pharma ENTA.O up 7.1% to $8.12
AbbVie says the U.S. FDA approves expanded use of its drug, Mavyret, for the treatment of adults and pediatric patients three years and older with hepatitis C virus (HCV) infection
Mavyret was first approved by the FDA in August 2017 to treat hepatitis C virus (HCV) infection in adults
Hepatitis C is a viral infection that causes liver swelling that can lead to serious liver damage
Mavyret was developed through a collaboration between AbbVie and Enanta Pharma
Including session's moves, ABBV up 8.3% and ENTA up 33.2% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.